Every 10-Q that STEMTECH CORP (STEK) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow STEK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full STEK filings page.
Stemtech Corporation reported continuing operating losses and severe liquidity pressure for the six months ended June 30, 2026. Net sales were $1,092,269, down from $1,565,971 in 2025, largely due to constrained inventory that limited distributor orders. Gross profit fell to $819,980 and gross margin declined to 75.1%. The company reduced operating expenses to $1,947,976 from $2,778,173, narrowing the operating loss to $1,127,996 and the net loss to $1,453,418.
Total assets were $3,163,559 against current liabilities of $11,112,964, resulting in a working capital deficit of about $10.5 million and a stockholders’ deficit of $8,216,405. Management states that recurring losses, negative cash flows, and dependence on external financing raise substantial doubt about the ability to continue as a going concern. The company relies on convertible notes, a discretionary $7.0 million senior secured convertible facility (of which $1,561,660 has been funded), factoring arrangements, and a new inventory financing agreement.
Capital structure is highly dilutive. Shares outstanding increased from 425,980,711 at December 31, 2025 to 2,738,521,585 at June 30, 2026, and to 2,997,032,856 by August 13, 2026, mainly through conversion of debt and stock issued for services and insider compensation. The company also discloses defaults under merchant cash advance agreements and ongoing litigation with a former CEO, for which $267,000 is accrued.
Stemtech Corporation reports Q1 2026 results with net sales of $462,957, down from $868,046 a year earlier, and a net loss of $1,252,880. Operating expenses fell by $477,267, and interest expense declined, narrowing the loss by about 14% year over year.
The balance sheet remains highly strained, with current liabilities of $11.1M versus current assets of $0.6M, creating a working capital deficit of about $10.5M and an accumulated deficit of roughly $36M. Management again raises substantial doubt about the company’s ability to continue as a going concern and highlights dependence on external financing, including a discretionary senior secured convertible facility and related-party loans.
Share count rose sharply to 1.65 billion at March 31, 2026 and 2.37 billion by June 22, 2026, mainly from stock issued for services and conversions of debt into equity, significantly diluting existing holders. Subsequent inventory financing of roughly $2.5M is intended to rebuild product availability and support future sales.
Stemtech Corporation (STEK) reported another loss-making quarter and raised going concern doubts in its Q3 2025 report. For the quarter ended September 30, 2025, net sales were $852,300, down from $1,031,630 a year earlier, as the company shifted away from lower-margin volume toward core markets. Despite lower revenue, cost controls helped reduce operating loss to $339,217 from $716,470, and net loss narrowed to $812,541 from $1,171,405.
For the nine months, sales fell to $2,418,271 from $3,740,000, but net loss improved to $2,567,547 from $3,376,121 as operating expenses declined by about $1.3 million. The balance sheet remains strained: assets were $3,755,801 against current liabilities of $10,301,779, resulting in a stockholders’ deficit of $6,545,978 and a working capital deficit of about $9.2 million.
Management explicitly concluded that substantial doubt about the company’s ability to continue as a going concern is not alleviated, citing recurring losses, negative operating cash flow, dependence on external financing, and defaults under certain Merchant Cash Advance agreements now in litigation. Stemtech is pursuing private equity raises, a proposed convertible debt facility, cost cuts, and international joint ventures to improve liquidity, but these plans are not yet committed or realized.